MedTrace Logo

Simvastatin for mTBI

NCT01952288 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2021-12-15

Study results available
· View outcomes & findings →

Summary

Study of simvastatin in Iraq/Afghanistan Veterans with multiple blast exposure and mTBI. The study will measure substances in cerebrospinal fluid (CSF) that are related to dementing disorders.

Conditions

  • TBI-Traumatic Brain Injury

Interventions

DRUG

simvastatin

simvastatin 40 mg/day for 12 months

DRUG

Placebo Oral Tablet

placebo comparator

Sponsors & Collaborators

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Elaine R Peskind, MD · VA Puget Sound Health Care System Seattle Division, Seattle, WA

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-16
Primary Completion
2017-06-20
Completion
2017-06-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01952288 on ClinicalTrials.gov